19381-40-9

Basic information

• Product Name: 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one
• Synonyms: 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one;2-Bromo-1-[3-(phenylmethoxy)phenyl]ethanone;Einecs 243-009-7;1-[3-(benzyloxy)phenyl]-2-broMoethan-1-one;1-(3-(benzyloxy)phenyl)-2-broMoethanone;Ethanone, 2-broMo-1-[3-(phenylMethoxy)phenyl]-;1-(3-(Benzyloxy);-2-bromoethanone
• CAS NO: 19381-40-9
• Molecular Formula: C₁₅H₁₃BrO₂
• Molecular Weight: 305.16652
• EINECS: 243-009-7
• Mol File: 19381-40-9.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 395.5 °C at 760 mmHg
• Flash Point: 193 °C
• Appearance: /
• Density: 1.394 g/cm³
• Vapor Pressure: 1.83E-06mmHg at 25°C
• Refractive Index: 1.603
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one(19381-40-9)
• EPA Substance Registry System: 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one(19381-40-9)

Safety Data

• Hazardous Substances Data: 19381-40-9(Hazardous Substances Data)

Usage

General Description

2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one is a chemical compound with the molecular formula C15H13BrO2. It is a synthetic organic compound that belongs to the class of ketones. 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one consists of a bromine atom attached to a carbon atom, which is in turn attached to a phenylmethoxyphenyl group and an ethanone group. It is used in organic synthesis and pharmaceutical research as a building block for the synthesis of various organic compounds. Its chemical properties and structure make it suitable for use in the development of new drugs and pharmaceuticals.

InChI:InChI=1/C15H13BrO2/c16-10-15(17)13-7-4-8-14(9-13)18-11-12-5-2-1-3-6-12/h1-9H,10-11H2

Upstream product

• 605-65-2 5-(dimethylamino)naphth-1-ylsulfonyl chloride 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 121-71-1 3-Hydroxyacetophenone 
• 34068-01-4 1-[3-(phenylmethoxy)phenyl]ethan-1-one 

Downstream Products

• 109741-79-9 1-(3-benzyloxyphenacyl)-3-ethylpyridinium bromide 
• 154621-69-9 (E,2R)-N-Benzyl-5-<2'-<3''-(benzyloxy)phenyl>-2'-oxoethylidene>proline tert-butyl ester 
• 884331-11-7 methanesulfonic acid 3-(2-{tert-butoxycarbonyl-[2-hydroxy-2-(3-hydroxy-phenyl)-ethyl]-amino}-propyl)-1H-indol-7-yl ester 
• 884331-33-3 benzenesulfonic acid 3-(2-{tert-butoxycarbonyl-[2-(7-methanesulfonyloxy-1H-indol-3-yl)-1-methyl-ethyl]-amino}-1-hydroxy-ethyl)-phenyl ester 
• 1027488-63-6 (2R,5R)-5-<2'-(3''-Hydroxyphenyl)ethyl>proline tert-butyl ester 
• 132687-68-4 3-Benzyloxyphenacyl 3-Pyridyl Ether 
• 132687-71-9 3-Benzyloxyphenacyl 3-Methoxyphenyl Ether 
• 1449488-08-7 2-(3-(benzyloxy)phenyl)-8-methyl-3-(methylthio)imidazo[1,2-a]pyridine 

Relevant articles and documents

Thin-layer chromatographic and high resolution mass spectrometric determination of beta-hydroxyphenylethylamines in tissues as dansyl-acetyl derivatives.

-

(THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS

The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

Tryptamine-based human β3-adrenergic receptor agonists. Part 3: Improved oral bioavailability via modification of the sulfonamide moiety

The continued SAR investigation of tryptamine-based human β3-adrenergic receptor (AR) agonists is reported. Prior efforts resulted in the identification of 2 as a potent β3-AR agonist. Further modification of the left side arylsulfonamide portion in 2 provided compounds with good cell permeability, which have potent agonistic activity for β3-AR. Cinnamylamine analog 16i exhibited an excellent agonistic profile in vitro and good oral bioavailability in rats.